Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
75 results about "Elafin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Elafin, also known as peptidase inhibitor 3 or skin-derived antileukoprotease (SKALP), is a protein that in humans is encoded by the PI3 gene.
Use of matrix metalloproteinase inhibitors in skin care
InactiveUS20090068255A1Preventing and reducing of and sun damageImprove skin appearanceBiocideCosmetic preparationsWrinkle skinDisease
The application of matrix metalloproteinase (MMP) inhibitors to the skin inhibits the degradation of proteins found in the skin including collagen, elastin, and other basement membrane and extracellular matrix protein. MMP inhibitors may be used in both cosmetic compositions and pharmaceutical compositions for application to skin. MMP inhibitors are formulated with a cosmetically suitable vehicle or pharmaceutically acceptable excipient for application to the skin as creams, lotions, ointments, solutions, face masks, etc. As cosmetics, the inventive MMP inhibitor compositions are applied to the skin to prevent or reduce the appearance of wrinkles, pigmentation changes, loss of elasticity, or other effects associated with aging or sun damage. As pharmaceuticals, the inventive MMP inhibitor compositions may also be applied to the skin to treat or prevent a skin disease (e.g., proliferative disease, inflammatory disease).
Owner:LIVING PROOF INC
Methods and compositions for the diagnosis of diseases of the aorta
InactiveUS20070224643A1Facilitate patient treatmentConvenient treatmentDiagnosticsSurgeryAortic dissectionSmooth Muscle Myosins
The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to the use of biomarkers, either individually or in combinations with one another to rule in or out diseases of the aorta and its branches, most particularly aortic aneurysm and / or aortic dissection, and for risk stratification in such conditions. Preferred markers include one or more of creatine kinase-BB (CK-BB), creatine kinase-MB (CK-MB), acidic calponin, basic calponin, B-type natriuretic peptide (BNP), NT-proBNP, proBNP, BNP79-108, BNP3-108, caldesmon, caspase-3, D-dimer, soluble elastin fragments, endothelial cell-selective adhesion molecule (ESAM), fibrillin-1, heart-type fatty acid binding protein, MMP-9, myeloperoxidase, myoglobin, smooth muscle myosin, smooth muscle myosin heavy chain, TIMP-1, free cardiac troponin I, complexed cardiac troponin I, free and complexed cardiac troponin I, free cardiac troponin T, complexed cardiac troponin T, and free and complexed cardiac troponin T, and preferred assays are configured to detect these markers.
Owner:BIOSITE INC
Elastin peptide analogs and methods of using same
InactiveUS6506731B1Increase elasticityImprove functionalityCosmetic preparationsDipeptide ingredientsGlycineElastin peptides
The present invention is directed to a composition which is used to enhance the elasticity and / or appearance of tissue. Specifically, the present invention is directed to a composition formulated from peptides having low molecular weights and which substantially correspond to sequences found in elastin More preferably, the present invention corresponds to the general formula R1-Leucine-Glycine-Alanine-Glycine-Glycine-Alanine-Glycine-R2.
Owner:CONNECTIVE TISSUE IMAGINEERING
Plant based formulations for improving skin moisture, texture, and appearance
ActiveUS7348034B2Increase moistureImprove textureCosmetic preparationsBiocideLipid formationAdditive ingredient
Owner:ACCESS BUSINESS GRP INT LLC
Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
ActiveUS20100004190A1Growth inhibitionReduce adhesionBiocideSugar derivativesDiseaseLymphatic Spread
This invention provides methods, processes, compounds and compositions for modulating the gene expression and modulating the secretion, expression, or synthesis of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regulating; wherein comprises inhibiting cancer growth, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, Glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the methods, processes, compounds and compositions are also for anti-angiogenesis; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer or cervix cancer.
Owner:PACIFIC ARROW
Compositions and methods for soft tissue augmentation
Owner:HUMACYTE INC
Compositions of a peptide targeting system for treating cancer
This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.
Owner:ARIZ PRECISION MEDICINE INC +1
Diagnostic biomarkers for vascular aneurysm
InactiveUS20090186370A1Increase propensityMicrobiological testing/measurementDisease diagnosisBiological activationBiomarker (petroleum)
Biomarkers for diagnosis and monitoring of vascular aneurysms are described in the context of the use of assays to measure a plurality of these biomarkers. Tissue degeneration, particularly elastin and / or collagen degradation, can be monitored within patient blood (serum) and / or urine to diagnose the presence, the progression, or the likelihood of rupture of aneurismal disease. Additionally, enzymes responsible for this degradation and other biomarkers responsible for the activation or inhibition of these enzymes can be monitored additionally or alternatively. Prompt diagnosis can provide the opportunity for intervention and potentially increase the health of patients by tempering the development of debilitating and life-threatening vascular aneurysms.
Owner:VATRIX MEDICAL INC
Method for discriminating between benign and malignant prostate tumors
The method for discriminating between benign and malignant prostate tumors relates to analyzing samples of blood, urine and tissue by fluorescence spectroscopy in order to detect the presence of naturally occurring molecules in the fluids and tissue that serve as biomarkers indicative of cancer in the human body. The analysis can be carried out based on fluorescence emission spectra, fluorescence excitation spectra and synchronous (emission and excitation) spectra of bio-samples. The detection, diagnosis, and follow-up and also discrimination between malignant and benign prostate tumors may be made by comparison of ratios of fluorescence emissions and / or excitation intensities of tryptophan, tyrosine, elastin, collagen, bile pigments, NADH, flavins and various species of porphyrins.
Owner:KING SAUD UNIVERSITY
Elastin digest compositions and methods utilizing same
InactiveUS7560430B2Stimulate endogenous productionIncrease elasticityCosmetic preparationsDipeptide ingredientsLigament structureDigestion
The present invention provides compositions for the therapeutic and / or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise epitopes of cytokines, growth factors and di-peptides. Methods of using these elastin digest comprising compositions for treating tissues in need of increased elasticity and or Elastin are described.
Owner:ELASTOGENESIS LLC
Agents with angiogenic and wound healing activity
InactiveUS20100210531A1Promote angiogenesisPeptide/protein ingredientsPeptide preparation methodsADAMTS ProteinsCell migration
The invention relates to the use of angiogenic crystallin proteins to promote angiogenesis, wound healing and / or endothelial cell migration. Alpha A crystallin and βB2 crystallin have particular application in these methods. The crystallins will usually be in monomeric form. Typically, truncated form(s) of βB2 crystallin protein are utilized as can be prepared by partial hydrolysis of the protein by a protease enzyme such as elastase I. Methods for the purification of crystallin proteins from eye tissue are also described.
Owner:CALLAGHAN INNOVATION +1
Skin compactness composition and application thereof
ActiveCN107308101AEven skin toneHigh activityCosmetic preparationsToilet preparationsWrinkle skinVitamin A Retinol
The invention relates to a skin compactness composition which comprises hyaluronic acid, hydrolyzed collagen, dipalmitoyl hydroxyproline, compound amino acid, decarboxylation peptide, acetyl hexapeptide, plankton extracts, lactic acid bacillus / soybean milk fermentation product filtrate, dipotassium glycyrrhizinate, retinyl palmitate, VE and hydrolyzed sesame protein. By the aid of anti-aging vitamin, amino acid, derivatives and peptides, an extracellular matrix structure matrix is endogenously improved, the dipalmitoyl hydroxyproline, palmityl glycine, the decarboxylation peptide, the acetyl hexapeptide, sodium hyaluronate, retinol, the hydrolyzed collagen, the plankton extracts, the lactic acid bacillus / soybean milk fermentation product filtrate and the dipotassium glycyrrhizinate serve as main components, thin wrinkles caused by skin laxity are comprehensively repaired, metalloprotease activity is inhibited by promoting collagen and elastin synthesis, skin compactness and elasticity are improved, and young skins are restored.
Owner:HUNAN YUJIA COSMETICS MFG CO LTD
Covalently attached collagen VI for cell attachment and proliferation
InactiveUS20050058687A1Promote proliferationEasy SurvivalBioreactor/fermenter combinationsBiological substance pretreatmentsCollagen VIPolymer
Surfaces useful for cell culture comprise a support to which is bound a CAR material, and, bound to the CAR material, collagen VI or a biologically active fragment or variant thereof and, optionally, one or more other ECM proteins (or fragments or variants thereof) such as elastin, fibronectin, vitronectin, tenascin, laminin, entactin, aggrecan, decorin, collagen I, collagen III, and collagen IV. Also, optionally present on the surface is one or more polycationic polymers, such as poly-D-lysine or poly-D-ornithine. This surface is used in cell culture to promote cell attachment, survival, and / or proliferation of a number of different cell types such as (a) liver cells (e.g., HepG2 tumor cells, and a newly discovered line of rat liver epithelial stem cells) (b) osteoblasts, such as the murine cell line MC3T3 cell line and (c) primary bone marrow cells. Kits comprising the surfaces and additional reagents are also disclosed.
Owner:BECTON DICKINSON & CO
Elastin peptide analogs and uses thereof
InactiveUS6962904B1Increase skin elasticityImprove skin appearanceCosmetic preparationsConnective tissue peptidesElastin peptidesPeptide fragment
The present invention is directed to a composition which is used to enhance the elasticity and / or appearance of tissue. Specifically, the present invention is directed to a composition formulated from peptides or peptide-like compounds having low molecular weights and which substantially correspond to sequences found in elastin. The present composition specifically includes chemical modification of the peptides described herein, specifically carboxy and amino modification including the addition of amino acids to either end of the peptide fragments.
Owner:CONNECTIVE TISSUE IMAGINEERING
Methods for predicting the development and resolution of acute respiratory distress syndrome
The subject invention features methods for predicting whether a subject at risk of developing Acute Respiratory Distress Syndrome (ARDS) will develop ARDS by determining the amount of elafin present in a subject sample, or by determining the ration of elafin:neutrophil elastase in a subject sample. The invention also features methods for monitoring the efficacy of a treatment regimen for ARDS as well as methods of treatment for ARDS. The invention also features methods to determine a subject's predisposition for developing ARDS by determining whether certain genomic polymorphisms are present in the subject's DNA.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Elastin-like polypeptides (ELP) for prokaryotic expression of fusion protein Prx by non-digestion and non-chromatography purifying method
ActiveCN104387473AEfficient and fast purificationPurify the economyBacteriaMicroorganism based processesElastin like polypeptidesProtein target
The invention discloses elastin-like polypeptides (ELP) for prokaryotic expression of fusion protein Prx by a non-digestion and non-chromatography purifying method and belongs to the field of genetic engineering. According to the elastin-like polypeptides, the type of the fourth amino acid in an elastin-like pentapeptide unit is changed and the elasticity function of the fourth amino acid is improved, and therefore, the reduction of the ELP length becomes possible. The ratio of K, V and F in the fourth basic group in the ELP pentapeptide unit is enabled to be 1: 6: 3. In terms of inteins, the high-efficiency intein gp41-1 is adopted; the C-terminal and the N-terminal of the intein are expressed separately, and the internal gene of the intein is mutated. The elastin-like polypeptides (ELPs) are ELP-IN and precursor protein ELP-IC-PrxI. The protein Prx is purified in a non-chromatography way by use of the elasticity function of the elastin-like polypeptides; no chromatographic column is required for separation, and the target protein precipitates by virtue of incubation at a certain temperature; besides, the precipitate can be re-dissolved in a buffer solution, and consequently, the protein can be purified more efficiently and quickly.
Owner:ZHENGZHOU UNIV
Novel Superactive IL-33 Fragments, and Uses Thereof
The present invention discloses novel active polypeptide fragments of human IL-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin G, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.
Owner:CENT NAT DE LA RECHERCHE SCI
Asparagine containing elastin peptide analogs
InactiveUS6794362B1Increase skin elasticityImprove skin appearanceBiocideCosmetic preparationsElastin peptidesElastin tissue
The present invention is directed to a composition which is used to enhance the elasticity and / or appearance of tissue. Specifically, the present invention is directed to a composition formulated from peptides or peptide-like compounds having low molecular weights and which substantially correspond to sequences found in elastin. The present composition specifically includes chemical modification of the peptides described herein, specifically carboxy and amino modification including the addition of amino acids to either end of the peptide fragments.
Owner:CONNECTIVE TISSUE IMAGINEERING
Plant-derived elastin binding protein ligands and methods of using the same
ActiveUS20090082280A1Good lookingImprove skin appearanceCosmetic preparationsHeavy metal active ingredientsElastin-binding proteinsElastin receptors
The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenesis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
Owner:HOSPITAL FOR SICK CHILDREN +1
Composition for improving skin condition and appearance
Owner:ARCH PERSONAL CARE PROD
Elastin peptide analogs and uses of same incombination with skin enhancing agents
The present invention is directed to a composition which is used to enhance the elasticity and / or appearance of tissue. Specifically, the present invention is directed to a composition formulated from peptides having low molecular weights and which substantially correspond to sequences found in elastin. These peptides are used in conjunction with or in combination with retinoids, preferably tretinoin.
Owner:CONNECTIVE TISSUE IMAGINEERING
Preparation method and application of conjugate of doxorubicin and double-targeting elastin-like polypeptide/anti-EGFR nanometer antibody/iRGD fusion protein
ActiveCN108187064AEasy to prepareGood water solubilityOrganic active ingredientsAntibody mimetics/scaffoldsEscherichia coliElastin like polypeptides
The invention discloses a double-targeting fusion protein based on elastin-like polypeptide (ELP), i.e., a double-targeting ELP / anti-EGFR nanometer antibody / iRGD fusion protein. The double-targeting fusion protein is prepared by constructing a recombinant plasmid containing ELP, an anti-EGFR nanometer antibody and an iRGD based on gene recombination technology and expressing and purifying the recombinant plasmid in Escherichia coli. The double-targeting fusion protein can be conjugated with the drug doxorubicin so as to form the ELP / anti-EGFR / iRGD double-targeting fusion protein doxorubicin conjugate. The ELP / anti-EGFR / iRGD double-targeting fusion protein doxorubicin conjugate has a hydration particle size of about 5 nm, mainly exists in the state of molecules and presents a good doxorubicin slow-release function and a good tumor cell-targeting function. The invention discloses a preparation method for the ELP / anti-EGFR / iRGD double-targeting fusion protein doxorubicin conjugate.
Owner:NANJING UNIV
Method for detecting post-transplantation GVHD related cytokines by applying flow cytometry and detection kit
PendingCN110988364AEnable multiple detectionReduce dosageBiological particle analysisDisease diagnosisPost transplantCytokine
The invention provides a method for detecting post-transplantation GVHD related cytokines by using flow cytometry and a detection kit. The method and the detection kit have important clinical significance in the aspects of early evaluation and diagnosis of post-transplantation GVHD. According to the detection method and the kit, indexes of one or more different combinations of cell factors IL-6, IL-8, ST2, Reg3[alpha], Elafin, TNFR1, soluble IL-2R and HGF related to GVHD diagnosis and prognosis can be rapidly and homogeneously detected at the same time; single-sample multiple detection is achieved, time and resources are saved, and the result is automatically analyzed by software so as to be more objective and accurate. The method is simple, convenient, safe in detection and small in sample use quantity. By the application of the method, the risk of the GVHD of the transplanted patient can be evaluated timely, quickly and stably for a long time, the accuracy and timeliness of treatmentof the patient are improved, and the life of the patient is saved.
Owner:天津美瑞特医疗科技有限公司
Elastin digest compositions and methods utilizing same
ActiveUS20090281044A1Promote productionIncrease elasticityBiocideCosmetic preparationsADAMTS ProteinsLigament structure
Owner:ELASTOGENESIS LLC
Composition of collagen peptide and elastin peptide, and preparation method and application of composition
InactiveCN109602896AIncrease contentReduced MMP3 contentCosmetic preparationsPeptide/protein ingredientsInflammatory factorsHydroxyproline
The invention relates to the technical field of food and medicines, and discloses a composition of a collagen peptide and an elastin peptide, and a preparation method and application of the composition. The composition of the present invention is composed of a collagen peptide and an elastin peptide, wherein the collagen peptide is produced by enzymolysis of a collagen material by pepsin or trypsin, and the elastin peptide is prepared by enzymolysis of an elastin material via papain and / or a complex protease Protamex. According to the present invention, the elastin peptide and collagen peptidein specific molecular weight ranges are prepared by specific processes, and form the composition at a suitable ratio. The composition can significantly increase the content of elastin and collagen indamaged skin at the same time in a small amount of use, significantly increase the content of hyaluronic acid and hydroxyproline and decrease the content of MMP3, and also can inhibit skin inflammatory factors.
Owner:INFINITUS (CHINA) CO LTD
Preparation and/or formulation of proteins cross-linked with polysaccharides
Therapeutic compositions and / or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and / or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and / or kits for the preparation and / or formulation of the compositions disclosed herein.
Owner:APTALIS PHARMA
Recombinant expression carrier and construction method and application thereof
ActiveCN110343183APromote independent high expressionHigh expressionPolypeptide with affinity tagHybrid peptidesDual promoterEscherichia coli
The invention relates to a high-expression recombination protein carrier pRELPN. The high-expression recombination protein carrier pRELPN is artificially synthesized ELP fusion protein(RELPN) consisting of 9 polyarginine (R9)-elastin polypeptide (ELP) n-10 poly asparagine (N10), when multiple clone sites cloned in pronucleus or eukaryotic expression vectors (p) are not directly expressed as exogenous genes, the effect of a second promoter can be achieved. The pRELPN carrier can promote independent high expression of an exogenous target gene behind start cipher ATG cloned behind ELP fusion protein. The fusion protein is seldom expressed, and self expression of hosts of escherichia coli or eukaryocyte and the like can be slightly restrained, so that recombination protein accumulation and high expression of the exogenous target gene can be promoted. The high expression vector pRELPN containing dual promoters is suitable for independent high expression of exogenous genes of antibodies, antigens, enzymes, recombination protein, polypeptide, ELP fusion protein and the like, so as to contribute to solving of the problem of disindustrialization caused by that a common expression vector islow or non in expression on an exogenous gene an exogenous gene or a fusion gene consisting of the exogenous gene and ELP.
Owner:点斗基因科技(南京)有限公司
Method for preparing recombinant N-terminal brain natriuretic peptide precursor based on elastin-like label
ActiveCN106222189AEfficient preparationFast preparationAntibody mimetics/scaffoldsNucleic acid vectorEscherichia coliGenetic recombination
The invention belongs to the field of biotechnology, and relates to amethod for preparing recombinant N-terminal brain natriuretic peptide precursor based on elastin-like label. The method comprises the following steps: cloning N-terminal brain natriuretic peptide gene onto a pET28a(+) / ELP[I]40 prokaryotic expression vector through genetic recombination, transferring the recombinant expression vector into Escherichia coli BL21(DE3) for expression, collecting thalli, then purifying the recombinant protein by adopting a repeated reversible transition cycling ITC method, wherein the protein is ELP[I]40-NT-proBNP recombinant protein. The method can fast, simply and efficiently purify a fusion protein with anti-NT-proBNP antibody binding activity, the recovery purity of the fusion expression protein can achieve 90% or more, thus providing a basis for preparing a standard substance with brain natriuretic peptide precursor antigenicity in high efficiency and low cost.
Owner:大连东方雍和生物科技发展有限公司
Method for purifying recombinant porcine circovirus 2 type Cap protein
PendingCN106543290AHigh recovery rateConnective tissue peptidesBacteriaFusion Protein ExpressionCircovirus
The invention relates to a method for purifying recombinant porcine circovirus 2 type Cap protein. The recombinant porcine circovirus 2 type Cap protein is composed of ELP type elastin polypeptide genes and PCV-ORF2 genes. A preparation method of the purifying recombinant porcine circovirus 2 type Cap protein comprises the steps of expression vector construction and fusion protein expressing and purifying. Compared with an existing porcine circovirus vaccine purifying method, the method for purifying the recombinant porcine circovirus 2 type Cap protein has the advantages that preparation is easy and convenient, purifying is easy, and the price is low, and is suitable for large-scale production operation, and a foundation is provided for preparation, purification and application of subsequent recombinant porcine circovirus subunit vaccines.
Owner:ZHONGCHONG XINNUO BIOTECH TAIZHOU CO LTD
Plant-derived elastin binding protein ligands and methods of using the same
ActiveUS7723308B2Good lookingImprove skin appearanceHeavy metal active ingredientsCosmetic preparationsElastin-binding proteinsElastin receptors
Owner:HOSPITAL FOR SICK CHILDREN +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com